Comparing two treatment approaches for multiple myeloma
Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study
Hospital General de Mexico · NCT06284395
This study looks at how well two different treatment combinations for multiple myeloma work in helping patients who are eligible for stem cell transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 83 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Hospital General de Mexico (other gov) |
| Locations | 1 site (Mexico City, Mexico City) |
| Trial ID | NCT06284395 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes medical records of patients with multiple myeloma who were eligible for stem cell transplantation and received either the VTD (bortezomib, thalidomide, and dexamethasone) or TD (thalidomide and dexamethasone) treatment regimens as their first-line therapy. The aim is to compare the effectiveness of these two treatment combinations in terms of response rates, survival outcomes, and time to subsequent treatments. By utilizing retrospective data, the study seeks to provide insights into the best treatment strategies for patients with limited resources.
Who should consider this trial
Good fit: Ideal candidates are patients with multiple myeloma who are eligible for stem cell transplantation and have received either the VTD or TD treatment.
Not a fit: Patients with incomplete clinical records or those who could not continue treatment due to economic or distance issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify the more effective treatment regimen for multiple myeloma, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown varying success with similar treatment approaches in multiple myeloma, but this specific comparison is less commonly explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs. Exclusion Criteria: * Incomplete clinical records * Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues * Clinical records of patients who presented severe sepsis before the beginning of either treatment
Where this trial is running
Mexico City, Mexico City
- Hospital General de Mexico Dr. Eduardo Liceaga — Mexico City, Mexico City, Mexico (RECRUITING)
Study contacts
- Study coordinator: Christian O Ramos Peñafiel, PhD
- Email: leukemiachop33@gmail.com
- Phone: +52 55 27892000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Response, Acute Phase, Survivorship, Multiple Myeloma, Bortezomib, Thalidomide, Acute Phase Response, Survival